- Clinical Trials
- April 2024
- 80 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- January 2024
- 160 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- January 2022
- 200 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2022
- 200 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2022
- 60 Pages
Global
From €3808EUR$3,950USD£3,257GBP
- Drug Pipelines
- June 2020
- 152 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- February 2024
- 78 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- November 2022
- 99 Pages
Global
From €1928EUR$2,000USD£1,649GBP
- Report
- May 2022
- 51 Pages
Global
From €1928EUR$2,000USD£1,649GBP
The Renal Anemia Drug market is a subset of the Hematological Drugs market, which includes drugs used to treat diseases related to the blood and blood-forming organs. Renal Anemia Drugs are used to treat anemia caused by chronic kidney disease, a condition in which the kidneys are unable to produce enough of a hormone called erythropoietin (EPO). EPO is responsible for stimulating the production of red blood cells, which carry oxygen throughout the body. Renal Anemia Drugs are typically administered intravenously or subcutaneously, and may include recombinant human EPO, iron supplements, and other drugs.
Some companies in the Renal Anemia Drug market include Amgen, Roche, Novartis, Pfizer, and Johnson & Johnson. Show Less Read more
